TX-SOFTSERVE
2.12.2021 13:07:03 CET | Business Wire | Press release
SoftServe , a leading digital authority and consulting company, has released its second bi-annual Sustainability Report . The report, prepared according to GRI Standards, highlights progress made against the company’s ongoing commitment to a sustainable business strategy, featuring key initiatives and achievements that positively impact society and the environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005018/en/
“As a global organization, we must take responsibility towards our associates, customers, and communities,” said Chris Baker, CEO at SoftServe. “SoftServe is a people-centric company, focused on creating an inclusive workplace that supports our associates’ well-being, access to education, and innovation, which enables us to support sustainable development in our communities around the world.”
“In 2020 the world faced extraordinary new challenges that impacted each of us as individuals, and as a business,” said Taras Vervega, co-founder and board member at SoftServe. “It was another moment that revealed who we are as a company. The way SoftServe responded to the pandemic, the numerous solutions we have created to help our clients, and the massive response of our company and our people to help hospitals and local communities – all make me very proud of the company we’ve built.”
Diversity, Equality, and Inclusion
Since 2018, SoftServe has made significant progress towards gender equality, as the rate of women in managerial roles grew from 35% in 2018 to 49% in 2020. Additionally, as part of its inclusivity efforts, in 2020 the company launched its first learning course in accessibility testing for visually impaired people , and its graduates are now part of SoftServe’s accessibility testing team.
Advancing IT Education
Developing IT education is another focus of the company’s social initiatives. SoftServe’s IT Academy , an educational platform for students and graduates, enrolled 2,759 students and subsequently hired 1,368 graduates upon completion of its programs over the last two years. SoftServe currently maintains partnerships with 34 universities and tech schools in Ukraine, Bulgaria, and Poland, establishing new IT bachelor’s degree programs, launching tech labs, and hosting numerous educational events.
Empowering Communities
SoftServe’s approach to social responsibility includes empowering its people to give back to their communities. In 2020 SoftServe became strategic partner to UNICEF Ukraine. The parties cooperated on educational programs and initiatives in Ukraine to exchange knowledge and professional experience and worked together on several pro bono technology solutions.
Throughout 2020, SoftServe built a framework to engage associates in pro bono projects that address pressing social issues and created the company’s Open Tech crowdsourcing platform. Together with NGOs and governmental institutions, SoftServe contributed to a number of projects, including Ukraine’s National Volunteer Platform , created with UNICEF Ukraine, the Ukrainian Volunteer Service, and the Ministry of Youth and Sports of Ukraine. The Platform is an online portal that helps connect volunteers with opportunities around social assistance, education and science, culture, art, and more.
SoftServe also developed a COVID-19 triage chatbot for the Bulgarian government to provide citizens with critical information, answers to frequently asked questions, and healthcare contact information to help assess symptoms and navigate the next steps. Using advanced conversational AI, the triage chatbot quickly assesses users with a series of text or voice questions, eliminating staff burden and soothing patient fears. It is an omnichannel communication tool available on any smartphone, computer, or tablet, and can help to triage patients in under 30 seconds.
Other key social achievements include:
- 4 international awards for SoftServe’s corporate social responsibility and sustainability initiatives and projects
- 92 volunteer and charitable projects accomplished in 2019–2020
- 50+ events launched dedicated to emotional health and employee well-being
- 752 computers donated to educational establishments in 2019-2020
- 10,000+ trees planted in 2019–2020
- $882,500 contributed to projects implemented by SoftServe’s “Open Eyes” charity fund in 2019–2020
- 10+ tons of medical equipment funded via SoftServe & “Open Eyes” charity fund
About SoftServe
SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, energy, financial services, software, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients’ users expect.
SoftServe delivers open innovation - from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience are built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy. No matter where you are in your journey.
Visit our website , blog , LinkedIn , Facebook , and Twitter pages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005018/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom